Evaluation of PD-L1 expression in recurrent nonmetastatic sacral chordomas – a retrospective study

Basit Öğe Kaydı
dc.authorscopusid36085521800
dc.authorscopusid56690141900
dc.authorscopusid57222477923
dc.authorscopusid58157800700
dc.authorscopusid23768513300
dc.authorscopusid12764256900
dc.authorscopusid57896383300
dc.contributor.authorZenginkinet, T.
dc.contributor.authorOkay, E.
dc.contributor.authorYıldırım, A.N.T.
dc.contributor.authorCelik, A.
dc.contributor.authorTurhan, Y.
dc.contributor.authorÖzkan, K.
dc.contributor.authorAkyürek, M.
dc.date.accessioned2023-07-26T11:50:27Z
dc.date.available2023-07-26T11:50:27Z
dc.date.issued2023
dc.departmentDÜ, Tıp Fakültesi, Cerrahi Tıp Bilimleri Bölümü, Ortopedi ve Travmatoloji Ana Bilim Dalıen_US
dc.description.abstractIntroduction/Objective Chordomas are rare tumors of a notochordal origin. Wide surgical resection is recommended for treatment. However, it is associated with a high risk of morbidity and mortality. Additionally, these tumors are resistant to chemotherapy. Thus, targeted therapy is needed for the treatment of chordomas. Programmed death ligand 1 (PD-L1) is a promising target for cancer treatment. Here, we investigated PD-L1 expression in patients with chordoma in a single-center study. Methods Formalin-fixed paraffin-embedded blocks were evaluated for immunohistochemical analysis to evaluate PD-L1 expression. Clinicopathological variables, such as sex, age, and follow-up data (recurrence and outcome), were retrospectively collected from the patients’ medical records. Results Ten patients diagnosed with sacral chordoma in a single institution between December 2015 and November 2021 were included in this study. The median patient age was 57 years and the median follow-up period was 40 months. The surgical margins were negative in all cases, without any preoperative medical treatment. Four of the ten patients showed PD-L1 positivity on immune cells. These patients showed local recurrence, without metastasis. In these cases, the median time to local recurrence was 15 months. All the patients with the disease were alive. Conclusion This study demonstrated that PD-L1 positivity in immune cells can be used as a predictive marker for local recurrence at the time of surgical treatment. This can potentially be used to determine the necessity to administer immunotherapy. © 2023, Serbia Medical Society. All rights reserved.en_US
dc.identifier.doi10.2298/SARH220524009Z
dc.identifier.endpage78en_US
dc.identifier.issn0370-8179
dc.identifier.issue1.Şuben_US
dc.identifier.scopus2-s2.0-85150914210en_US
dc.identifier.scopusqualityQ4en_US
dc.identifier.startpage74en_US
dc.identifier.urihttps://doi.org/10.2298/SARH220524009Z
dc.identifier.urihttps://hdl.handle.net/20.500.12684/12349
dc.identifier.volume151en_US
dc.identifier.wosWOS:000996441100011en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakScopusen_US
dc.institutionauthorTurhan, Y.
dc.language.isoenen_US
dc.publisherSerbia Medical Societyen_US
dc.relation.ispartofSrpski Arhiv za Celokupno Lekarstvoen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.snmz$2023V1Guncelleme$en_US
dc.subjectchordomaen_US
dc.subjectimmunotherapyen_US
dc.subjectPD-L1en_US
dc.subjectwide surgical resectionen_US
dc.titleEvaluation of PD-L1 expression in recurrent nonmetastatic sacral chordomas – a retrospective studyen_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
12349.pdf
Boyut:
1.18 MB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu